Secukinumab approved by NICE for severe psoriasis

The monoclonal antibody secukinumab (Cosentyx) has been endorsed by NICE for use in patients with severe plaque psoriasis who have not responded to, or have an intolerance or contraindication to, standard systemic therapies

Plaque psoriasis: new treatment for patients with severe disease (Photograph: iStock)
Plaque psoriasis: new treatment for patients with severe disease (Photograph: iStock)

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days
  • Join GPOnline now and pay nothing for the first 30 days

Sign Up Sign Up